HK1250944A1 - 用於治疗癌症的方法 - Google Patents

用於治疗癌症的方法 Download PDF

Info

Publication number
HK1250944A1
HK1250944A1 HK18110438.9A HK18110438A HK1250944A1 HK 1250944 A1 HK1250944 A1 HK 1250944A1 HK 18110438 A HK18110438 A HK 18110438A HK 1250944 A1 HK1250944 A1 HK 1250944A1
Authority
HK
Hong Kong
Prior art keywords
methods
treating cancer
compound
kits
administering
Prior art date
Application number
HK18110438.9A
Other languages
English (en)
Chinese (zh)
Inventor
Chiang J. Li
Wei Li
Youzhi Li
Matthew J. HITRON
Yuan Gao
Original Assignee
Boston Biomedical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical, Inc. filed Critical Boston Biomedical, Inc.
Publication of HK1250944A1 publication Critical patent/HK1250944A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18110438.9A 2015-04-17 2016-04-18 用於治疗癌症的方法 HK1250944A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US201562149349P 2015-04-17
US201662280947P 2016-01-20 2016-01-20
US201662280947P 2016-01-20
PCT/US2016/028177 WO2016168856A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Publications (1)

Publication Number Publication Date
HK1250944A1 true HK1250944A1 (zh) 2019-01-18

Family

ID=55854799

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110438.9A HK1250944A1 (zh) 2015-04-17 2016-04-18 用於治疗癌症的方法

Country Status (16)

Country Link
US (1) US20180085341A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283069A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018511643A (cg-RX-API-DMAC7.html)
KR (1) KR20180006918A (cg-RX-API-DMAC7.html)
CN (1) CN107666906A (cg-RX-API-DMAC7.html)
AU (1) AU2016247319A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017022281A2 (cg-RX-API-DMAC7.html)
CA (1) CA2983010A1 (cg-RX-API-DMAC7.html)
EA (1) EA201792287A1 (cg-RX-API-DMAC7.html)
HK (1) HK1250944A1 (cg-RX-API-DMAC7.html)
IL (1) IL255022A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017013360A (cg-RX-API-DMAC7.html)
PH (1) PH12017501879A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201900564WA (cg-RX-API-DMAC7.html)
TW (1) TW201713327A (cg-RX-API-DMAC7.html)
WO (1) WO2016168856A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
EP3405189A1 (en) * 2016-01-20 2018-11-28 Boston Biomedical, Inc. Methods for treating cancer
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
WO2019050924A1 (en) * 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
JP7513286B2 (ja) * 2018-10-12 2024-07-09 １グローブ バイオメディカル カンパニー， リミテッド 化学療法難治性がんの治療のための新しい併用薬方法
EP3705893A1 (en) * 2019-03-05 2020-09-09 Humanitas Mirasole S.p.A. Methods to assess the risk of being affected by prostate cancer
SG11202110338XA (en) * 2019-03-27 2021-10-28 Singapore Health Serv Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
WO2011116398A1 (en) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Novel compounds and compositions for targeting cancer stem cells
ES2987670T3 (es) 2010-03-19 2024-11-15 1Globe Biomedical Co Ltd Métodos novedosos para actuar sobre células madre cancerosas
JP2014511384A (ja) 2011-03-04 2014-05-15 ゾウシャン ハイジョンジョウ シンシェン ファーマシューティカルズ カンパニー リミテッド 疾患治療のための４，９−ジヒドロキシ−ナフト［２，３−ｂ］フランの新規エステル
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
CA2908380A1 (en) * 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
EP3405189A1 (en) * 2016-01-20 2018-11-28 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
CN107666906A (zh) 2018-02-06
JP2018511643A (ja) 2018-04-26
AU2016247319A1 (en) 2017-11-02
IL255022A0 (en) 2017-12-31
SG11201708504XA (en) 2017-11-29
BR112017022281A2 (pt) 2018-07-10
US20180085341A1 (en) 2018-03-29
TW201713327A (zh) 2017-04-16
EA201792287A1 (ru) 2018-03-30
CA2983010A1 (en) 2016-10-20
MX2017013360A (es) 2018-08-01
SG10201900564WA (en) 2019-02-27
EP3283069A1 (en) 2018-02-21
KR20180006918A (ko) 2018-01-19
PH12017501879A1 (en) 2018-03-05
WO2016168856A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
AU2022231657A1 (en) Compositions and Methods for Treating Cancer
HK1258098A1 (zh) 治疗癌症的方法
HK1250944A1 (zh) 用於治疗癌症的方法
EP3258966A4 (en) Methods, compositions, and kits for treatment of cancer
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
IL254722A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
EP3393475A4 (en) METHODS OF TREATING CANCER
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
IL261015A (en) History of methylamine as lysis oxidase inhibitors for cancer treatment
IL268163A (en) Methods, compositions, and kits for treatment of cancer
EP4616910A3 (en) Pcna inhibitors
MX2016009663A (es) Derivados de icariina.
EP3394047A4 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
EP4169918B8 (en) Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
EP3548007A4 (en) METHOD OF TREATMENT OF CANCER
PH12017501880A1 (en) Methods for treating cancer
EP3487999A4 (en) METHODS OF TREATING CANCER
EP3296294A4 (en) Compound for treating or preventing breast cancer
EP3303289A4 (en) Compounds and methods for treating cancer
EP3630754B8 (en) Isoindoline-acetylene compounds for the treatment of cancer
EP3592357A4 (en) METHOD OF TREATMENT OF CANCER
EP3242681B8 (en) Novel compounds for the treatment of cancer
EP3268028A4 (en) Compositions and methods for treating cancer
EP3285763A4 (en) Compositions for the treatment of cancer